Checkmate Pharmaceuticals is conducting studies of CMP-001 in combination with nivolumab for the treatment of advanced, PD-1 refractory melanoma and first-line (PD-1-naïve) melanoma. Melanoma is a serious form of skin cancer that arises from a particular skin cell type called a melanocyte. This form of skin cancer is particularly dangerous because of its ability to rapidly spread to other organs if not surgically removed at an early stage, as well as its low response rates and limited durability of response when treated with commonly used chemotherapeutics. In 2020, melanoma of the skin is estimated to be the fifth most diagnosed cancer, and accounts for approximately 1% of all skin cancers in the U.S. According to the American Cancer Society, there will be an estimated 100,350 new diagnoses and approximately 6,850 patients will die as a result of melanoma in the United States in 2020.
Links to Clinical Trials
Head and Neck Squamous Cell Carcinoma (HNSCC)
CMP-001 is also under investigation in combination with pembrolizumab for the first-line treatment of metastatic or unresectable head and neck squamous cell carcinoma (HNSCC). Head and Neck Squamous Cell Carcinoma (HNSCC) represents a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth, and accounts for approximately 3.6% of all cancers in the United States. HNSCC is more than twice as prevalent among men. Treatments for HNSCC can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments including immunotherapy.